| Identification | Back Directory | [Name]
Epelsiban | [CAS]
872599-83-2 | [Synonyms]
Epelsiban
GSK 557296
(3R,6R)-6-[(2S)-butan-2-yl]-3-(2,3-dihydro-1H-inden-2-yl)-1-[(1R)-1-(2,6-dimethylpyridin-3-yl)-2-morpholin-4-yl-2-oxoethyl]piperazine-2,5-dione
2,5-Piperazinedione, 3-(2,3-dihydro-1H-inden-2-yl)-1-[(1R)-1-(2,6-dimethyl-3-pyridinyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1S)-1-methylpropyl]-, (3R,6R)- | [Molecular Formula]
C30H38N4O4 | [MDL Number]
MFCD26961099 | [MOL File]
872599-83-2.mol | [Molecular Weight]
518.65 |
| Chemical Properties | Back Directory | [Boiling point ]
790.6±60.0 °C(Predicted) | [density ]
1.214±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [pka]
13.16±0.60(Predicted) |
| Hazard Information | Back Directory | [Uses]
Epelsiban (GSK 557296) is a potent, selective and orally bioavailable oxytocin receptor antagonist, with a pKi of 9.9 for human oxytocin receptor. | [Definition]
ChEBI: Epelsiban is a dipeptide. | [in vivo]
Epelsiban shows an IC50 of 192 nM for oxytocin receptor in rats. Epelsiban has low levels of intrinsic clearance against the microsomes of rat, dog, and cynomolgus monkey, good bioavailability (55%), but is negative in the genotoxicity screens with a satisfactory oral safety profile in female rats[1]. | [References]
[1] Borthwick AD, et al. Pyridyl-2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists: synthesis, pharmacokinetics, and in vivo potency. J Med Chem. 2012 Jan 26;55(2):783-96. DOI:10.1021/jm201287w |
|
|